CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 79 enrolled
Drug / intervention
VERITAS Vision Systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04332640
NCT04332640N/ACompleted
CompareCT.gov

Clinical Investigation of the Next Generation Phaco System (VERITAS Vision System)

Johnson & Johnson Surgical Vision, Inc.·interventional·Posted Apr 2, 2020·Updated Jun 15, 2022

In Brief

A clinical study evaluating VERITAS Vision System for Cataract. Completed, enrolled 79 participants across 2 sites in 2 countries.

Detailed Summary

This study is a prospective, open-label clinical study of the VERITAS Vision System. The study will be conducted at up to three sites, with minimum 55 eyes and up to 150 eyes to be treated. The investigator or designee will perform the cataract surgery with the VERITAS Vision System on the subjects. The data from the system log files, the questionnaire, the operative report and other medical records will be used to assess the clinical utilization of the VERITAS Vision System.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCataract
CountriesEl Salvador, United States
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedApr 2, 2020
Enrollment StartSep 28, 2020
Primary CompletionMay 1, 2021
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 6.3 years ago

Interventions

VERITAS Vision Systemdevice

The investigators or designees will perform routine small-incision cataract surgery via phacoemulsification and use the VERITAS Vision system. The Investigator or designee will then complete a questionnaire regarding the clinical use of the VERITAS Vision system. The system log files automatically generated by the VERITAS Vision system after completion of each surgery will be collected.